IBD Live: First Look

TL;DR

Pharmacy giant's stock drops 4% on earnings, while Nasdaq rebounds after successful test of 21-day moving average.

Transcript

yes uh the pharmacy giant uh they were down four percent on their results after the close we'll have abtr that's avantur and roku and uh avantara remains on the leaderboard in addition to them etsy will also report and that's uh all the news for now send it back okay thank you dave now we turn our attention to the nasdaq here's stinkers from td ame... Read More

Key Insights

• 💦 The pharmacy giant's stock drop highlights the importance of closely monitoring earnings reports and managing risk accordingly.
• 🥳 The successful test of the 21-day moving average for the Nasdaq indicates potential market strength and a bullish trend.
• 🍝 HZNP's promising earnings gap presents a potential opportunity, but caution is advised due to the stock's past volatility.
• ✋ Traders should focus on elite stocks with strong fundamentals and a history of robust earnings performance for higher conviction trades.
• 😀 The market's resilience in the face of morning volatility emphasizes the importance of not making impulsive decisions and letting positions play out.
• 🥹 The rebound in the Nasdaq and positive market sentiment may indicate a favorable environment for earnings gaps to hold and move higher.
• ❓ The biotech sector, including HZNP, requires a deeper understanding and conviction for successful trading due to its inherent volatility.

Questions & Answers

Q: Why did the pharmacy giant's stock go down by 4% after its earnings report?

The drop can be attributed to the market's reaction to the company's earnings performance, which may not have met investors' expectations.

Q: What was the significance of the successful test of the 21-day moving average for the Nasdaq?

The successful test indicates that the market is finding support at this moving average, suggesting a potential bullish trend for the Nasdaq.

Q: How is Horizon Therapeutics (HZNP) behaving in the market?

HZNP showed a promising earnings gap, but its previous volatility has made traders cautious about adding it back to their portfolios.

Q: What is the recommended approach for trading the earnings gap of HZNP?

It is suggested to manage risk and consider adding to an existing position rather than starting a new one, especially considering the stock's historical choppiness and volatility.

Summary & Key Takeaways

• The pharmacy giant's stock decreased by 4% after the release of their earnings report.

• The Nasdaq experienced a successful test of the 21-day moving average and rebounded, showing positive signs.

• Horizon Therapeutics (HZNP) has shown a promising earnings gap, but traders are cautious due to its previous volatility.